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Abstract
Introduction: The diagnosis, management, and treatment for hepatitis C virus (HCV) infection (the “HCV care
continuum”) have improved in recent years. People who use drugs (PWUD) have a prevalence of HCV infection
from 30 to 70 %, yet rates of testing, engagement in care, and treatment for HCV are disproportionately low
compared to other populations. Delineating the progression of PWUD through the steps in the HCV care
continuum in the USA is important in informing efforts to improve HCV outcomes among PWUD.
Methods/design: Scientific databases will be searched using a comprehensive automated search strategy; gray
literature and reference lists will be manually searched. Eligible reports will provide original research data related to
the HCV care continuum in the USA including proportions of PWUD engaging in the following discrete steps:
screening/testing, engagement in care (including receiving an HCV clinical assessment), treatment initiation and
completion, and rates of those with successful HCV treatment. A quality-rating tool will be developed to ascertain
the level of bias (including selection bias) in each report, and a quality score will be assigned to each eligible
report. A tool adapted from the Pragmatic Explanatory Continuum Indicator Summary-2 instrument will be
developed to assess the extent to which an included report reflects an effectiveness or efficacy study design.
Pooled estimates and measures of association will be calculated using random effects models, and heterogeneity
will be assessed at each stage of data synthesis.
Discussion: Through this review, we hope to quantify the proportion of PWUD at each progressive step and to
help identify key individual, social, and structural points of leakage in the HCV care continuum for PWUD. In
meeting these objectives, we will identify predictors to progress along the HCV care continuum, which can be used
to inform policy to directly improve HCV care for PWUD.
Systematic review registration: PROSPERO CRD42016034113
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Introduction
Hepatitis C virus (HCV) is a chronic, life-threatening
blood-borne infection that affects an estimated 150 million
people globally [1]. It is most efficiently transmitted by per-
cutaneous exposure, which makes people who inject drugs
(PWID) at particularly high risk [2, 3]. In the USA, there
are an estimated 1.86 million PWID, of whom 1.5 million
(74 %) are believed to be HCV antibody positive [4]. People
who use drugs (PWUD) administered via smoking or inhal-
ation are also at risk as a result of unprotected sex and
sharing pipes or straws that may be blood contaminated
[5, 6]. Additionally, there have been outbreaks of HCV
among prescription opioid users who have recently
transitioned to drug injection, as well as among HIV-
positive men who have sex with men [7–12]. PWUD
are often infected with HCV at an early age and thus
are at risk for developing liver fibrosis, cirrhosis, and
hepatocellular carcinoma in mid-adulthood, potentially
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resulting in morbidity and mortality among individuals
in their most productive period of life [13–16]. Projections
suggest that increases in the incidence of HCV-related cir-
rhosis and its complications will continue for at least two
to three decades [16]. Among HCV mono-infected individ-
uals, an estimated 20–25 % will develop liver disease, which
may manifest as fibrosis, cirrhosis, end-stage liver disease,
or hepatocellular carcinoma [15]. HIV co-infection acceler-
ates this progression [17, 18].
HCV treatment has the potential to significantly reduce
morbidity and mortality associated with chronic HCV in-
fection [19, 20]. There have been dramatic advances in the
ability to treat chronic HCV infection; more efficacious and
tolerable medications requiring shorter treatment courses
can lead to a sustained virologic response (SVR), which pre-
dicts reduced liver disease morbidity and mortality in a ma-
jority of treated patients. In addition to improvements with
treatment, there have been improvements in screening
methods and in diagnosis [19–24].
However, among PWUD, there are very significant
gaps in the HCV care continuum that reduce the real-
world population-level effectiveness of HCV treatment
[25–28]. Among PWUD with HCV infection, many have
not been screened or, if screened, are unaware they are
infected; they may be tested for HCV antibody (a meas-
ure of the previous exposure but not necessarily the
current active infection) but not for viral load to confirm
active infection, and the majority are not evaluated for
treatment or offered treatment [28–31]. Following treat-
ment and cure, they may also be at risk of re-infection
due to continuous exposure to HCV infection through
persistent risk behaviors [32, 33].
This systematic review and meta-analysis (SR/MA) will
focus on the HCV care continuum for PWUD. The HCV
care continuum will be examined considering the following
steps: initial screening for HCV antibodies, confirmatory
diagnosis with HCV RNA testing, and provider evaluation
for treatment; offer, acceptance, and initiation of treatment;
adherence to treatment; completion of treatment; and
achievement of SVR. This SR/MA will also examine rates
of re-infection among those who achieved SVR.
Methods
This protocol was developed in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-Analysis Protocols (PRISMA-P) guidelines [34].
A populated PRISMA-P checklist is provided for this
protocol as Additional file 1.
Exposure measures
The primary exposures examined in this review include
(1) being a current PWUD or PWID and therefore being
at risk for HCV infection and (2) being a current or
former PWUD or PWID and having HCV infection.
Chronic HCV infection is defined as the presence of
HCV viremia. The term “PWUD” will be used to refer
those who use or have used any illicit drug or drugs by
any route, but will exclude those who use, or have used,
alcohol, tobacco, or marijuana only. The term PWID will
be used to refer to those who use or have used any illicit
drug by injection.
Inclusion and exclusion criteria
This study will include published and unpublished data
from both observational (prospective and retrospective
cohort, case-control, and cross-sectional) and experimental
(randomized controlled trials, hybrid designs, and quasi-
experimental trials) study designs. Reports published in
English from January 1, 1990, through February 20, 2016,
will be included if they report on the rates of transition of
the past or current PWUD or PWID from at least one step
of the care continuum to another. PWUD with either HCV
mono-infection or co-infection with HCV/HIV will be in-
cluded in this review. Reports must include ten or more
subjects who are former or current PWUD. If data is pre-
sented for both those who do and do not have a history of
drug use, the report must provide disaggregated data on
PWUD or PWID.
For the purposes of this SR/MA, drug use will be de-
fined as the use of any drug, either licit or illicit, with
the exception of the exclusive use of alcohol, tobacco, or
marijuana. Four populations that will be specifically ex-
amined include (1) people who currently inject drugs,
(2) people who formerly injected drugs, (3) people who
currently use drugs without injecting, and (4) people
who formerly used drugs without injecting. Reports will
be eligible if they examine people in one or more of these
four groups as they are identified as having completed one
or more steps on the HCV care continuum.
Inclusion criteria will require that reports present data
from the USA, as the progression through steps in the
care continuum is highly dependent on the type of
healthcare delivery system in a given country. Thus, we
will restrict our initial analysis for this SR/MA to the
progression of PWUD through the HCV care continuum
in the USA. However, we will retain the list of non-US
studies that are otherwise eligible for inclusion for
possible analysis at a later date.
Outcome measures
Care continuum steps to be considered will include (a)
HCV antibody screening (where testing only confirms
exposure to the HCV virus and not HCV viremia) and
subsequent confirmatory HCV viral load testing (where
HCV viremia or chronic HCV infection is ascertained);
(b) linkages to next steps of HCV clinical evaluation,
including evaluation for appropriate HCV treatment and
offer of HCV pharmacological treatment (evaluation for
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HCV treatment may include liver biopsy, liver bio-
markers (e.g., FIB-4), and non-invasive transient liver
elastography), and offer of HCV treatment involves either
a verbal recommendation for treatment by a provider or
receipt of a written prescription; (c) interventions to in-
crease patient engagement, which includes acceptance of
treatment, initiation of treatment, and adherence to treat-
ment (acceptance of treatment is willingness to begin
treatment for HCV; initiation of treatment refers to taking
one or more prescribed HCV medication at least once;
and adherence refers to taking a specified proportion of
prescribed HCV medication for a specified time, as de-
fined by the studies reviewed); (d) completion of treat-
ment refers to remaining in treatment until finishing
the entire length of the prescribed treatment regimen;
(e) achieving SVR is defined as having undetectable
HCV RNA 24 weeks after completion of treatment (or
at a specified time post-treatment as defined by the
studies included in the review); and (f ) re-infection is
defined as those who have a positive HCV RNA test
with a different HCV genotype or strain within 1 year
of having previously achieving SVR. Each successive
step in the HCV care continuum is dependent on passing
through the previous step.
Each step in the HCV care continuum is contingent
upon completion of the previous step. Therefore, each
outcome measure listed previously is also a measure of
exposure, with the exception of the last step (re-infec-
tion). We will present data for PWUD as a whole and
for the subset of PWUD who are PWID where such data
are available so that the proportions of PWUD attribute
to PWID are made explicit.
Search strategy
After consultation with a medical librarian, a search
strategy will be conducted of PubMed, Embase, the
Cumulative Index of Nursing and Allied Health Litera-
ture, and PsycInfo. A preliminary search strategy for
each of these four databases is provided in Additional
file 2. Keywords and MeSH terms will be included in
the search if they relate to hepatitis C infection, past
or current drug use, and any step along the care con-
tinuum. Ancestry searches will be conducted of reviews
found in the search for additional relevant literature, and
unpublished literature will be obtained by searching
conference abstracts and contacting authors where appro-
priate. Conference abstracts to be searched include the
College on Problems of Drug Dependence (CPDD), the
American Association for the Study of Liver Diseases
(AASLD), the European Association for the Study of the
Liver (EASL), the International Harm Reduction Confer-
ence (IHRC), and the Conference on Retroviruses and
Opportunistic Infections (CROI).
Screening and data collection
Reports obtained from the search strategy will be imported
into EndNote X7.5 and duplicates will be removed. The
project director (PD; AEJ) and research assistant (RA; JR)
will screen each abstract retrieved from the automated
searches and discard those abstracts that are clearly in-
eligible. Full-text articles that are deemed as potentially
eligible will be retrieved, and the report will be evaluated
by the PD and RA to determine whether the article meets
the inclusion criteria. Reasons for exclusion during full-
text review will be recorded and presented as per the
PRISMA guidelines. The principal investigator (PI; HH),
co-investigator (Co-I; DCP), and PD will screen all articles
that were unclear as to whether or not they meet the in-
clusion criteria on the initial review.
A final set of eligible articles will be compiled for
coding. The coding will be carried out by the PD and
RA. The content and structure of the coding form will
be tailored to collect data on the numbers and propor-
tions of PWUD completing each step of the HCV care
continuum. The coding form will include study design
elements and sample characteristics (e.g., demographic
information) and will be designed to be flexible in




Screening and data abstraction will be conducted by the
PD and RA, both of whom have graduate-level training
in the research methodology of systematic reviews and
meta-analyses, as well as additional training in the epi-
demiology of HCV and drug use. Periodic staff meetings
will be conducted to resolve any questions or inconsist-
encies in the extraction and analysis of the data. A study
guide will be created to guide the process and record
special cases and their resolution.
Study quality and critical appraisal
The quality of each included report will be assessed
using a quality-rating tool adapted from the assessment
of risk of bias studies developed by Hayden et al. [35].
The quality-rating tool will assess threats to validity, includ-
ing selection bias, non-comparability, and misclassification.
Categorization of study design
Reports will be evaluated with respect to the degree to
which they have features reflecting either efficacy or effect-
iveness study design elements, using an adaptation of the
Pragmatic Explanatory Continuum Indicator Summary-2
(PRECIS-2) instrument [36, 37]. PRECIS-2 is designed to
assist in the designing of studies [37]; we will adapt the
instrument to facilitate post hoc evaluation. Studies are
typically not purely efficacy studies or effectiveness studies
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but instead fall somewhere on the efficacy/effectiveness
continuum. The adapted PRECIS-2 tool will allow us to
evaluate where the reports included in this review fall on
this continuum.
Selection bias
In case-control studies, selection bias will be evaluated
by examining whether adequate methods were used to
classify cases and controls and whether cases and
controls came from the same underlying population. In
cohort studies, selection bias will be assessed to deter-
mine if selection of the cohort was related to the likeli-
hood of their progression through the care continuum.
Comparability
Comparability of cases and controls will be assessed by
ensuring that methods were used to adjust for con-
founding between the two groups. In cohort studies,
comparability will be assessed by ensuring that the
association between the exposure and the outcome
adjusted for important differences between the exposed
and unexposed cohorts.
Misclassification
It is important that the studies included in this review
provide an explicit definition of each exposure and out-
come in order to avoid misclassification. In addition,
misclassification will be addressed as part of eligibility
screening; for example, inclusion criteria will require
that HCV infection be confirmed via serology testing to
avoid misclassification of exposure.
Data analysis
Beginning February 2016, we will conduct database
searches using appropriate keywords and download all
relevant titles to EndNote version X7.5 for data
management.
The analyses will define each step in the continuum
discretely for each report, from testing to SVR, and
aggregate the study-level data for synthesis. Synthesis will
begin with the search for homogeneous subsets within
sets of studies, followed by meta-analysis and calculation
of summary estimates within the homogeneous subsets.
Graphical and statistical analysis will be conducted using
software designed specifically for meta-analysis.
If the systematic review results in a small number of
studies for the meta-analysis, the estimates of heterogen-
eity among the included studies may be inappropriately
low (as an artifact of the small number of studies) [38].
We will be wary of this and will not assume homogen-
eity in the presence of low heterogeneity, and we will
not conduct simple fixed-effects meta-analysis; meta-
analysis and random effects meta-regression will be
carried out instead.
Variability in effects among the studies may reflect im-
portant differences or confounding by other factors. There-
fore, the evidence of heterogeneity will be evaluated at each
step in the analysis to distinguish between true variation of
effects and heterogeneity due to other differences. We will
report both I2 and H2 with confidence intervals as measures
of heterogeneity, since I2 alone is not sufficient when
conducting meta-analyses on a small number of studies
[39]. Subgroup analyses of those with or without HIV
co-infection will be assessed as well after review of the
included studies to determine if differences exist in the
HCV care continuum between these two groups.
Publication bias will be assessed if the final analysis
consists of at least ten studies, since this is the minimum
number required to achieve adequate power [40]. This
will be accomplished by comparing estimates between
published and unpublished reports and by the use of
funnel plots.
Discussion
This systematic review and meta-analysis will critically
assess the progression of PWUD through the steps in
the HCV care continuum. We anticipate the benefits of
this review to be twofold: first, we anticipate that this
review will quantify the proportion of PWUD at each pro-
gressive step in the care continuum and, thus, present a
robust characterization of the engagement of PWUD in
the sequential steps of the HCV care continuum that can
be used in modeling and public health planning efforts.
Second, we hope that this review will help identify key in-
dividual, social, and structural bottlenecks or points of leak-
age in the care continuum. In addition to identifying the
proportions of PWUD/PWID progressing through care
continuum steps, we will examine studies for the presence
of covariates which, if reported and present, may be associ-
ated with progression through care continuum steps in an
attempt to identify barriers to and facilitators of progres-
sion. This will help identify points where interventions are
needed to improve individual and population-level progress
through the care continuum and will help to elucidate
modifiable barriers, facilitators, and predictors of progres-
sion through the care continuum, including those relevant
at each step and those relevant to achieving SVR via HCV
treatment. Additionally, the review’s focus on providing
HCV re-infection rates post-SVR among PWUD has the
potential to inform interventions on secondary prevention
of re-infection among high-risk individuals.
Additional files
Additional file 1: PRISMA-P 2015 Checklist.
Additional file 2: Search strategy for CINAHL (via EBSCO), Embase
(via Ovid), PsycInfo (via Ovid), and PubMed (via Medline).
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